Risk of Symptomatic DVT Associated With Peripherally Inserted Central Catheters

Evans, R. Scott; Sharp, Jamie H.; Linford, Lorraine; Lloyd, James F.; Tripp, Jacob S.; Jones, Jason P.; Woller, Scott C.; Stevens, Scott M.; Elliott, C. Gregory; Weaver, Lindell K.

doi:10.1378/chest.10-0154

Cited by 230 publications

(194 citation statements)

References 26 publications

Supporting

Mentioning

167

Contrasting

Unclassified

Order By: Relevance

“…Recent trials of hospitalized patients have defined PRLVT as thrombosis affecting the deep veins or the large superficial veins (basilic or cephalic) in the proximal upper extremity or neck. Rates of PRLVT are documented between 3 and 58% [4][5][6][7]. Importantly, the highest rates of PRLVT are reported from patient populations who have required PICC placement in the intensive care unit (ICU) [5,7].…”

Section: Introductionmentioning

confidence: 99%

“…Importantly, the highest rates of PRLVT are reported from patient populations who have required PICC placement in the intensive care unit (ICU) [5,7]. Conversely, the rate of large vein thrombosis related to CICVCs is reported to be much lower, in the range of 0-10% in ICU patients, after excluding the femoral site [5,6,8,9].…”

Section: Introductionmentioning

confidence: 99%

“…Some authors have suggested PRLVT, whether superficial or deep, is almost entirely asymptomatic [3,5,10,11]. Conversely, a large portion of the existing literature consists of retrospective or prospective observational studies in which thrombosis was identified on imaging studies obtained due to symptoms, most commonly pain, swelling or erythema in the ipsilateral arm [4,6,12,13]. In addition, a recently halted prospective study using routine ultrasound in an ICU patient population demonstrated 20% of patients developed symptomatic PRLVT [7].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The Clinical Significance of Peripherally Inserted Central Venous Catheter-Related Deep Vein Thrombosis

2011

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Clinical Significance of Peripherally Inserted Central Venous Catheter-Related Deep Vein Thrombosis

2011

View full text Add to dashboard Cite

show abstract

“…Além deste, há um estudo que mostra a preponderância da seleção ao membro superior direito (13) . Uma pesquisa mostrou que o membro superior direito tem maior taxa de sucesso de inserção na primeira tentativa do que o membro superior esquerdo (14) .…”

Section: Discussionunclassified

Característica Dos Cateteres E De Crianças Portadoras De Doença Oncohematológica

Machado

Moura²,

Cunha³

et al. 2017

Cogitare Enferm.

View full text Add to dashboard Cite

CHARACTERISTIC OF CATHETERS AND OF CHILDREN WITH ONCOHEMATOLOGICAL DISEASEABSTRACT: The objective in this study was to identify the clinical profile of children/adolescents with onco-hematological diseases and the characteristics of the catheters they use. Descriptive study with quantitative approach of 78 epidemiological surveillance forms. The scenario was a pediatric onco-hematology outpatient clinic. The data were collected in August 2015. It was observed that 32 (59%) of the patients using a totally implanted catheter were male, and seven (53%) patients with a peripherally inserted central venous catheter were female. Ages ranged between 10 and 16 years. The main diagnosis was acute lymphoid leukemia in both. The mean length of use of the totally implanted catheter was 303 days, against 55 days for the peripherally inserted central venous catheter. The end of the treatment is the main motive for the withdrawal of both. The lack of completed information in the forms limited this research. In conclusion, these devices are effective and safe for chemotherapeutic treatment. DESCRIPTORS: Child; Hematology; Catheters; Nursing; Chemotherapy. CARACTERÍSTICA DE LOS CATÉTERESY DE NIÑOS PORTADORES DE ENFERMEDAD ONCO-HEMATOLÓGICARESUMEN: La finalidade del estudio fue identificar el perfil clínico de niños/adolescentes con enfermedad onco-hematológica, así como las características de los catéteres utilizados por ellos. Estudio descriptivo, con abordaje cuantitativo de 78 fichas de registro epidemiológicas. El contexto fue el de un ambulatorio de onco-hematología pediátrica y los datos fueron obtenidos en agosto de 2015. Se observó que 32 (59%) de los portadores de catéter totalmente implantado eran de sexo masculino, y que siete (53%) de los portadores de catéter epicutáneo eran de sexo feminino; la edad variaba entre 10 y 16 años; el diagnóstico principal fue el de leucemia linfoide aguda en ambos sexos. La media de utilización del catéter totalmente implantado fue de 303 días, mientras del catéter epicutáneo fue de 55 días; el término del tratamiento es el principal motivo de retirada de ambos. La falta de informaciones en las fichas de registro fue un factor limitador de esta investigación. Se concluye que estes dispositivos son eficaces y seguros para tratamiento quimioterápico.

show abstract

“…A prospective study of 444 cancer patients found that 4.3% developed symptomatic VTE [31]. A prospective study of 2,144 PICC catheters found a similar rate of thrombosis (3%) [32]. Although early studies of VTE prophylaxis employing low dose warfarin and dalteparin demonstrated protection [33,34], subsequent studies have been negative [35,36].…”

Section: Anticoagulants In Vte Prevention In Cancer Patientsmentioning

confidence: 99%

Anticoagulation in the management of venous thromboembolism in the cancer patient

Streiff

2011

J Thromb Thrombolysis

View full text Add to dashboard Cite

Cancer is associated with a four to sevenfold increased risk of venous thromboembolism (VTE). This risk is influenced by the site and extent of cancer and its treatment. Despite its availability, effective VTE prophylaxis is used in less than 50% of oncology patients. Pharmacologic VTE prophylaxis should be administered to all hospitalized medical and surgical oncology patients for the duration of their hospitalization or up to 10-14 days, whichever is longer. Extended duration (up to 4 weeks post-operation) VTE prophylaxis is recommended for high-risk surgical oncology patients. Routine use of prophylaxis in ambulatory medical oncology patients awaits prospective testing of VTE risk assessment models. Routine prophylactic dose anticoagulation to prevent central venous catheter (CVC) thrombosis is ineffective and not indicated. Low molecular weight heparin is the first line choice for acute and chronic therapy of VTE in cancer patients. Therapy should continue for at least 3 months or the duration of the malignancy, whichever is longer. Anticoagulation is indicated for at least 3 months or the duration of the catheter for CVC thrombosis. Preliminary data indicate that some cancer patients with pulmonary embolism may be managed as outpatients. Prospective validation of these studies and testing of current risk assessment strategies in oncology patients is warranted. Management of recurrent VTE and unsuspected VTE in the cancer patient are also reviewed.

show abstract

Risk of Symptomatic DVT Associated With Peripherally Inserted Central Catheters

Cited by 230 publications

References 26 publications

The Clinical Significance of Peripherally Inserted Central Venous Catheter-Related Deep Vein Thrombosis

The Clinical Significance of Peripherally Inserted Central Venous Catheter-Related Deep Vein Thrombosis

Característica Dos Cateteres E De Crianças Portadoras De Doença Oncohematológica

Anticoagulation in the management of venous thromboembolism in the cancer patient

Contact Info

Product

Resources

About